1. Home
  2. CET vs AVLN Comparison

CET vs AVLN Comparison

Compare CET & AVLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CET

Central Securities Corporation

HOLD

Current Price

$52.21

Market Cap

1.6B

Sector

Finance

ML Signal

HOLD

Logo Avalyn Pharma Inc. Common Stock

AVLN

Avalyn Pharma Inc. Common Stock

N/A

Current Price

$30.71

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CET
AVLN
Founded
1929
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.3B
IPO Year
N/A
2026

Fundamental Metrics

Financial Performance
Metric
CET
AVLN
Price
$52.21
$30.71
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
34.4K
405.5K
Earning Date
01-01-0001
N/A
Dividend Yield
5.12%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$6.93
N/A
Revenue Growth
N/A
N/A
52 Week Low
$47.13
$30.27
52 Week High
$54.65
$33.24

Technical Indicators

Market Signals
Indicator
CET
AVLN
Relative Strength Index (RSI) 44.34 N/A
Support Level $50.69 N/A
Resistance Level $52.20 N/A
Average True Range (ATR) 1.25 0.00
MACD -0.11 0.00
Stochastic Oscillator 36.47 0.00

Price Performance

Historical Comparison
CET
AVLN

About CET Central Securities Corporation

Central Securities Corp is a non-diversified closed-end management investment company. The company's investment objective is long-term growth of capital. It invests in common stocks, bonds, convertible bonds, preferred stocks, convertible preferred stocks, warrants, options real estate, or short-term obligations of governments, banks, and corporations.

About AVLN Avalyn Pharma Inc. Common Stock

Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.

Share on Social Networks: